Course of Islet Autoantibody Titers During Ig-immunoadsorption in a Patient with Newly Diagnosed Type 1 Diabetes

Seidel, D.; Geiss, H.C.; Donner, Markus G.; Ritter, Michael M.; Schwandt, P.; Koll, Robert; Standl, Eberhard; Ziegler, Anette‐G.

doi:10.1006/jaut.1998.0195

Cited by 10 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reported that the initial anti‐GAD was 129 Units, and the average reduction of anti‐GAD by one IA treatment was only 9.4% . The inconsistency of the results of percent reduction of anti‐GAD in two reports was speculated to be due to the difference of the anti‐GAD measurement procedures . The present study is the first report that investigates the removal kinetics of anti‐GAD by various plasmapheresis modalities and the circulating anti‐GAD dynamics during IA therapy in neurological disorders.…”

Section: Discussionmentioning

confidence: 71%

See 1 more Smart Citation

Removal Kinetics of Antibodies Against Glutamic Acid Decarboxylase by Various Plasmapheresis Modalities in the Treatment of Neurological Disorders

et al. 2014

View full text Add to dashboard Cite

Plasmapheresis is one of the acute treatment modalities for neurological disorders associated with antibodies against glutamic acid decarboxylase (anti-GAD). However, there is little information about the removal kinetics of anti-GAD by various plasmapheresis modalities. Here, we investigated the removal rate of anti-GAD and fibrinogen (Fib) by immunoadsorption (IA), plasma exchange using a conventional plasma separator (OP-PE), and plasma exchange using a high cut-off selective membrane plasma separator (EC-PE) in two cases of anti-GAD-associated neurological diseases. In case 1, IA and OP-PE were used, and the percent reductions were as follows: anti-GAD: 38.2% and 69.1% and Fib: 67.7% and 68.2%, respectively. In case 2, OP-PE and EC-PE were used, and the percent reductions were as follows: anti-GAD: 65.8% and 48.5% and Fib: 68.5% and 19.8%, respectively. OP-PE could remove anti-GAD more efficiently than IA. Further, EC-PE could maintain coagulation factors such as Fib better than IA and OP-PE. It is important to select the appropriate plasmapheresis modality on the basis of the removal kinetics.

show abstract

Section: Discussionmentioning

confidence: 71%

“…On the other hand, Seidel et al. reported that the initial anti‐GAD was 129 Units, and the average reduction of anti‐GAD by one IA treatment was only 9.4% . The inconsistency of the results of percent reduction of anti‐GAD in two reports was speculated to be due to the difference of the anti‐GAD measurement procedures .…”

Section: Discussionmentioning

confidence: 99%

Removal Kinetics of Antibodies Against Glutamic Acid Decarboxylase by Various Plasmapheresis Modalities in the Treatment of Neurological Disorders

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Follow-up sera were available for 4 of the glima 38 antibody positive subjects (Table 1: U38, U47, U76, U9). One of these patients (U76) underwent plasmapheresis and purified immunoglobulin G (IgG) from one treatment was used to prepare an immunoaffinity resin for glima 38 (Table 1: U80; [18]). The purified IgG fraction is positive for ICA, insulin autoantibodies IAA, GADA and IA-2A and has a concentration of IgG fivefold lower than in the patient's original serum sample (U76; data not shown).…”

Section: Methodsmentioning

confidence: 99%

Peptide mapping and characterisation of glycation patterns of the glima 38 antigen recognised by autoantibodies in Type I diabetic patients

et al. 2000

View full text Add to dashboard Cite

“…Using different antibodies this technology has been used to eliminate autoantibodies and immune complexes from plasma. Pilot studies have been performed in newly diagnosed diabetes mellitus type 1 (14) and dilatated cardiomyopathy (15,16).…”

mentioning

confidence: 99%

Extracorporal Low‐density Lipoprotein Elimination by Immunoadsorption

Ritter¹,

Parhofer

2003

Ther Apher Dial

View full text Add to dashboard Cite

Low-density lipoprotein (LDL) apheresis has proven its therapeutic usefulness in patients who suffer from coronary heart disease but cannot achieve LDL cholesterol concentrations defined by the National Cholesterol Education Program guidelines. Immunoadsorption was the first commercially available apheresis technique. It is based on affinity chromatography. As with other apheresis techniques, immunoadsorption has specific advantages and disadvantages. These have to be taken into account when selecting an apheresis technique for the individual patient.

show abstract

Course of Islet Autoantibody Titers During Ig-immunoadsorption in a Patient with Newly Diagnosed Type 1 Diabetes

Cited by 10 publications

References 20 publications

Removal Kinetics of Antibodies Against Glutamic Acid Decarboxylase by Various Plasmapheresis Modalities in the Treatment of Neurological Disorders

Removal Kinetics of Antibodies Against Glutamic Acid Decarboxylase by Various Plasmapheresis Modalities in the Treatment of Neurological Disorders

Peptide mapping and characterisation of glycation patterns of the glima 38 antigen recognised by autoantibodies in Type I diabetic patients

Extracorporal Low‐density Lipoprotein Elimination by Immunoadsorption

Contact Info

Product

Resources

About